Literature DB >> 12498709

Vaccination against tumor neovascularization: Promise and reality.

Shahin Rafii1.   

Abstract

Immunization against angiogenic-associated antigens selectively expressed on tumor vasculature provides for a novel strategy to block tumor growth. The feasibility of this approach has recently been borne out in several reports demonstrating that the protein or DNA of angiogenic molecules, such as VEGF-R2, can be used as vaccines to generate an effective cytotoxic T cell and antibody response against tumor vessels, thereby blocking tumor growth and metastasis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12498709     DOI: 10.1016/s1535-6108(02)00208-8

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  7 in total

1.  A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth.

Authors:  Lars Holmgren; Elena Ambrosino; Olivier Birot; Carl Tullus; Niina Veitonmäki; Tetyana Levchenko; Lena-Maria Carlson; Piero Musiani; Manuela Iezzi; Claudia Curcio; Guido Forni; Federica Cavallo; Rolf Kiessling
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

2.  Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo.

Authors:  Robert D Loberg; LaShon L Day; Rodney Dunn; Linda M Kalikin; Kenneth J Pienta
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

3.  Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature.

Authors:  John G Facciponte; Stefano Ugel; Francesco De Sanctis; Chunsheng Li; Liping Wang; Gautham Nair; Sandy Sehgal; Arjun Raj; Efthymia Matthaiou; George Coukos; Andrea Facciabene
Journal:  J Clin Invest       Date:  2014-03-18       Impact factor: 14.808

4.  Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors.

Authors:  Manabu Hatano; Naruo Kuwashima; Tomohide Tatsumi; Jill E Dusak; Fumihiko Nishimura; Karlyne M Reilly; Walter J Storkus; Hideho Okada
Journal:  J Transl Med       Date:  2004-11-24       Impact factor: 5.531

Review 5.  Targeting the tumor vasculature to enhance T cell activity.

Authors:  Evripidis Lanitis; Melita Irving; George Coukos
Journal:  Curr Opin Immunol       Date:  2015-02-06       Impact factor: 7.486

Review 6.  Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer.

Authors:  Emilie Uldry; Seraina Faes; Nicolas Demartines; Olivier Dormond
Journal:  Int J Mol Sci       Date:  2017-06-30       Impact factor: 5.923

7.  Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression.

Authors:  Stefano Pierini; Abhishek Mishra; Renzo Perales-Linares; Mireia Uribe-Herranz; Silvia Beghi; Andrea Giglio; Sergei Pustylnikov; Francesca Costabile; Stavros Rafail; Augusto Amici; John G Facciponte; Costantinos Koumenis; Andrea Facciabene
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 12.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.